Late Breaking Trials Submission Rules and Guidelines
The EHRA EUROPACE Programme Committee has adopted the following procedures for the presentation of clinical trials at the Late Breaking Trials session during the EHRA EUROPACE 2013.
These sessions provide notable exposure and recognition for studies likely to impact clinical practice. The trials will be selected by the EHRA EUROPACE Programme Committee with this in mind.
- Submissions are possible online through our dedicated application forms only.
- Applications must be submitted in English with accurate grammar and spelling.
- Please note that any medical research involving human subjects must conform to the principles of the Declaration of Helsinki of the World Medical Association. We remind you that patient’s photo should be avoided and the patient must never be identifiable in your presentation.
- Abstract submitted on animal studies: Study must follow the "Principles of laboratory animal care" (NIH Publication no. 85-23 revised 1985) and according to the national law if applicable.
- Please follow all instructions for completing the submission. We recommend you structure the content into purpose/background, methods, results and conclusion (if known) sections.
- The submission deadline is Tuesday 19 March 2013, midnight French Time (CET).
- After the deadline, the system will be closed, and submissions will be forwarded to the review committee. Changes or corrections will not be possible after the deadline. If you would like to withdraw an application already submitted, please notify us as quickly as possible at firstname.lastname@example.org stating the title of the application.
- Results will be sent individually to each submitter by e-mail early April. All accepted applications will be included in Late Breaking Trials session as an oral presentation with discussant.
Description of sessions and applications:
Late Breaking Trials are sessions reserved for first presentations of the primary endpoint(s) of recently or about to be completed clinical trials.
Applications should contain data of a recently completed clinical trial which has not been presented anywhere previously. Although the data may be submitted to a journal for consideration, they should not be published before the date of the presentation at the EHRA EUROPACE 2013.
Embargo and Publication:
The clinical trial results presented at the session are embargoed until they are presented during EHRA EUROPACE 2013. Clinical trial sponsors must comply with the embargo. The embargo means that results from the trial cannot be presented or announced in any forum (written or oral) except at closed investigator meetings prior to the congress. Presentation in Satellite Symposia prior to the session is also prohibited.
The submitter, on behalf of all co-authors, accepts responsibility to ensure that data is not disclosed prior to the session itself. Should circumstances arise in which the trial organisers consider prior disclosure, total or in part, it is imperative that ESC is consulted.
All oral presentation slides will be, for educational purposes, available on the ESC website. If you do not wish for your presentation slides to be featured on the website (post-presentation date and post-congress), please indicate so when transferring the copyrights to ESC.
By transferring the copyrights the submitter agrees, on behalf of all co-authors, to transfer and assign to the ESC the rights to edit, publish, reproduce, distribute copies and prepare derivative works such as press release. This includes use in indexes or search databases in print, electronic, or other media.
- Submission of an application constitutes a commitment by the author(s) to present if accepted. Failure to present and register for the meeting, if not justified, will jeopardise future acceptance of applications.
- Satellite Symposia occurring prior to the Late Breaking Trials Session cannot present the data contained in this session. A symposium can be organised after the session. Prior presentation to the trial investigators is acceptable.
- Abstracts submitted on the same trial through the standard abstract submission procedure for the EHRA EUROPACE 2013 will be withdrawn from the programme if the trial is presented in a Late Breaking Trials Session. In this case, please indicate the abstract number(s) on the application form.
Affirmation of originality and copyright transfer statement:
- The submitter hereby affirms that the work submitted is original, except for extracts from copyrighted works fully authorised by the copyright holders, and that all statements declared as facts are based on thorough examination and investigation for accurateness.
- By submitting your work to the ESC, you consent to have authors’ names, affiliation and biographical material being used in connection with the publication of your work.
- Author(s) represents and warrants that he/she/they is/are sole author(s) of the work, that all authors have participated in and agree with the content and conclusions of the work, and that the work is original and does not infringe upon any copyright, proprietary, or personal right of any third party.
- Submitting/Presenting published or already presented work will jeopardize future acceptance.
- The content belongs to the author(s). However if the abstract is accepted the submitter agrees, on behalf of all co-authors, to transfer and assign to the ESC the rights to edit, publish, reproduce, distribute copies and prepare derivative works such as press release. This includes use in indexes or search databases in print, electronic, or other media.
- Author(s) retain the right, after presentation at the Congress, to subsequently include the work in articles, books, or derivative works that he/she authors or edits provided said use does not imply the endorsement of the ESC.
- The submitter signs for all co-authors and accepts responsibility on the present rules for submission and presentation for transferring copyright on behalf of all co-authors.
Declaration of interest (DOI):
The Congress Programme Committee requests all presenters to disclose potential conflict of interest regarding their presentation in the first slide. This will allow the audience to take potential conflicts of interest into account when assessing the objectivity of the presentation.
A potential conflict of interest may arise from various relationships, past or present, such as employment, consultancy, investments and stock ownership, funding for research, family relationship, etc.
By certifying that you have read these Submission rules, you also confirm having received the prior approval from the co-authors to provide their data to the ESC. You have personal data, which is, according the Law on data processing and Civil Liberties 78-17 of 6 January 1978 modified, registered with the European Society of Cardiology (ESC). The information you supply on this application is required to process it and it will be held in the ESC customer data files. It may be used for marketing and communication purposes by the ESC and its contractors only. You have the absolute right to access, amend and oppose any use of this personal data by writing to the ESC at the address mentioned below:
THE EUROPEAN HEART HOUSE
2035 Route des Colles
Les Templiers BP 179
06903 Sophia Antipolis - France